Overview

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Status:
Completed
Trial end date:
2016-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with cystic fibrosis (CF).
Phase:
Phase 2
Details
Lead Sponsor:
Corbus Pharmaceuticals Inc.